1 June 1991 in Journal of Cell Science
We have examined the effects of β-xylosides, which act as exogenous acceptors for glycosaminoglycan chain initiation, on the morphology and proteoglycan biosynthesis of PC 12 pheochromocytoma cells, and on monolayer, aggregate and explant cultures of early postnatal rat cerebellum. PC 12 cells cultured for 13 days in the presence of nerve growth factor (NGF) and β-xyloside, and labeled during days 11-13 with sodium [35S]sulfate, showed an 8- to 11-fold increase in [35S]sulfate-labeled macromolecules released into the culture medium. Most of the increase was accounted for by chondroitin sulfate, which was in the form of free glycosaminoglycan chains, which were not acid-precipitable. The presence of β-xylo-side also led to a 65-115% increase in [35S]sulfate incorporation into cell-associated glycosaminoglycans and glycoproteins of untreated and NGF-treated PC 12 cells, respectively. β-Xyloside treatment reduced the size of the chondroitin sulfate chains in both the cells and medium from approximately 34 000 to 10000Mr, but had much less effect on heparan sulfate, which decreased in size from 16000 to 13 000-14 500 Mr (in the medium and cells, respectively). β-Xyloside inhibition of proteoglycan biosynthesis was accompanied by significant morphological effects in NGF-treated PC12 cells, consisting of an increase in length and decrease in the branching, diameter and adhesion to the collagen substratum of the PC 12 cell processes. p-Nitrophenyl- and 4-methylumbelliferyl-β-D-xylosides produced similar effects, which were not seen with p-nitrophenyl-β-D-galactoside. fi-Xylosides also produced distinct alterations in the adhesion and morphology of monolayer, aggregate, and explant cultures of early postnatal rat cerebellum, which occurred together with inhibition of chondroitin sulfate proteoglycan biosynthesis and a decrease in glycosaminoglycan chain size. These studies indicate that chondroitin sulfate (and probably also heparan sulfate) proteoglycans play a significant role in modulating cell-cell and cellmatrix interactions in nervous tissue development and differentiation.
30 April 2024 in Concilium
Gout is a form of self-limiting inflammatory arthritis caused by hyperuricemia and the deposition of monosodium urate (MSU) crystals in joint tissues. This deposition causes the activation of the NLRP3 inflammasome, thus triggering an inflammatory cascade. Intense activation of the NLRP3 inflammasome is associated with the pathogenesis of several inflammatory diseases, including gout. For this reason, this inflammasome has become a potential target for controlling this type of inflammation. In this review, 33 publications were selected from the Google Scholar, Scielo and PubMed platforms, thus providing a comprehensive perspective on the condition of gout and its relationship with the NLRP3 inflammasome. This review provides a broad view of the inflammatory process associated with gout, focusing on the NLRP3 inflammasome. In this context, interventions targeting these inflammasome and IL-1 pathways appear promising for the treatment of this disease.
1 January 2025 in Brazilian Journal of Biology
In the course of an infection, increased pro-inflammatory cytokines cause diseased individuals to develop a set of adaptive behavioral changes, collectively termed as sickness behavior. The administration of the endotoxin LPS, the main component of the outer membrane of Gram-negative bacteria, leads to activation of the immune system, inducing inflammatory process in experimental models. A new carboxymidamide (DCHA), which has potential anti-inflammatory activity, may be a promising candidate in the development of a new drug for inflammatory diseases and control of sickness behavior. This study was conducted to evaluate the effects of a novel carboxymidamide on lipopolysaccharide-induced sickness behavior in mice. The animals were submitted to open field tests and forced swimming two hours after treatment with LPS (100 µg/kg). In addition, the mRNA expression of iNOS and pro-inflammatory cytokines (IL-1β, TNF-α and IL-6) from the blood, liver and kidney of these animals was also evaluated using quantitative real-time PCR. The administration of lipopolysaccharide (LPS, 100 µg/kg, i.p.) induced behavioral changes in the mice, such as decreased locomotor and exploratory activity in the open field test and an increase in the time the animal remained floating in the forced swimming, as well as increased mRNA expression of iNOS and the pro-inflammatory cytokines IL-1β, TNF-α and IL-6. Pretreatment with the new carboxymidamide attenuated the behavioral changes induced by LPS, and significantly reduced the expression of iNOS and pro-inflammatory cytokines in mice. Thus, our experimental results demonstrated that DCHA attenuated the sickness behavior induced by LPS. These results suggest that the observed pharmacological effect is due to the in vivo anti-inflammatory action via reduction of pro-inflammatory cytokines.